Your browser is no longer supported. Please, upgrade your browser.
CLSD Clearside Biomedical, Inc. monthly Stock Chart
CLSD [NASD]
Clearside Biomedical, Inc.
Index- P/E- EPS (ttm)-2.66 Insider Own1.80% Shs Outstand32.04M Perf Week2.33%
Market Cap56.39M Forward P/E- EPS next Y-1.47 Insider Trans-20.66% Shs Float29.80M Perf Month-67.88%
Income-77.70M PEG- EPS next Q-0.57 Inst Own69.70% Short Float4.27% Perf Quarter-74.04%
Sales0.06M P/S1025.28 EPS this Y-127.60% Inst Trans-7.46% Short Ratio2.91 Perf Half Y-86.69%
Book/sh1.38 P/B1.28 EPS next Y42.40% ROA-102.80% Target Price5.86 Perf Year-75.18%
Cash/sh2.03 P/C0.87 EPS next 5Y- ROE-142.50% 52W Range1.42 - 15.33 Perf YTD-74.86%
Dividend- P/FCF- EPS past 5Y- ROI-198.70% 52W High-88.52% Beta-
Dividend %- Quick Ratio4.60 Sales past 5Y- Gross Margin- 52W Low23.94% ATR0.47
Employees34 Current Ratio4.60 Sales Q/Q- Oper. Margin- RSI (14)27.78 Volatility12.74% 13.52%
OptionableYes Debt/Eq0.22 EPS Q/Q-3.00% Profit Margin- Rel Volume0.96 Prev Close1.76
ShortableYes LT Debt/Eq0.22 EarningsNov 08 BMO Payout- Avg Volume436.46K Price1.76
Recom2.30 SMA20-49.47% SMA50-64.58% SMA200-79.51% Volume0 Change0.00%
Nov-05-18Downgrade Stifel Buy → Hold
Nov-05-18Downgrade JP Morgan Overweight → Underweight
Nov-05-18Downgrade Cowen Outperform → Market Perform
Mar-06-18Reiterated Needham Buy $18 → $22
May-25-17Initiated JMP Securities Mkt Outperform $21
Feb-24-17Initiated JP Morgan Overweight $19
Nov-10-16Reiterated Needham Buy $16 → $24
Oct-24-16Reiterated Stifel Buy $13 → $23
Nov-09-18 07:37AM  Edited Transcript of CLSD earnings conference call or presentation 8-Nov-18 1:30pm GMT Thomson Reuters StreetEvents -6.84%
Nov-08-18 07:00AM  Clearside Biomedical Announces Third Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire -9.82%
Nov-07-18 04:30PM  Clearside Biomedical to Participate in Stifel 2018 Healthcare Conference GlobeNewswire
Nov-06-18 06:55AM  Todays Research Reports on Stocks to Watch: Teladoc Health and Clearside ACCESSWIRE +7.25%
Nov-05-18 04:30PM  Clearside Biomedical to Report Third Quarter 2018 Financial Results on Thursday, November 8, 2018 Conference Call to Follow GlobeNewswire -62.77%
02:23PM  Major Stock Movers: Inuvo, Clearside Biomedical, Cirrus Logic, and More Insider Monkey
07:00AM  Clearside Biomedical Announces SAPPHIRE Phase 3 Study of Combination Therapy in Retinal Vein Occlusion Did Not Meet Its Primary Endpoint GlobeNewswire
Oct-29-18 10:25AM  Presentation of Additional Analyses of Clearsides PEACHTREE Clinical Trial Data Further Supports Potential of XIPERE in Treating Uveitic Macular Edema GlobeNewswire -11.48%
Oct-25-18 08:00AM  Clearside Biomedical Appoints Thomas A. Ciulla, M.D., MBA as Chief Medical Officer GlobeNewswire +14.68%
Oct-22-18 04:30PM  CLEARSIDE, XIPERE and PEACHTREE to be Front and Center at AAO 2018 GlobeNewswire
Oct-19-18 08:00AM  Clearside Biomedical Appoints Veteran Supply Chain Executive, Thomas Crawford, as Vice President, Supply Chain GlobeNewswire
Oct-16-18 07:30AM  Detailed Research: Economic Perspectives on Clearside Biomedical, JELD-WEN Holding, L.B. Foster, Merrimack Pharmaceuticals, Everi, and Drive Shack What Drives Growth in Today's Competitive Landscape GlobeNewswire
Sep-26-18 04:30PM  Clearside Biomedical Appoints Jeffrey Edwards to Board of Directors GlobeNewswire
Sep-18-18 04:30PM  Positive PEACHTREE Data to be Highlighted at EURETINA 2018 GlobeNewswire
10:45AM  What Investors Should Know About Clearside Biomedical Incs (NASDAQ:CLSD) Financial Strength Simply Wall St.
Sep-13-18 08:00AM  Data From Clearside Biomedicals Pivotal Phase 3 PEACHTREE Clinical Trial in Macular Edema Associated with Non-Infectious Uveitis to be Presented at the Retina Society 51st Annual Scientific Meeting GlobeNewswire +7.23%
Sep-12-18 04:30PM  Clearside Biomedical Appoints Viral Kansara as Vice President, Discovery GlobeNewswire
Sep-11-18 04:30PM  Clearside Biomedical Appoints Accomplished Pharmaceutical Industry Legal Executive, Leslie Zacks, as General Counsel and Chief Compliance Officer GlobeNewswire
Sep-10-18 04:30PM  Clearside Biomedical to Participate in 2018 Janney Healthcare Conference GlobeNewswire
Sep-06-18 04:30PM  Clearside Biomedical Further Strengthens Commercial Organization With Appointment of Lester Rodríguez as Vice President, Quality GlobeNewswire
Aug-17-18 08:15AM  Analysis: Positioning to Benefit within Armstrong Flooring, U.S. Global Investors, Aqua Metals, Clearside Biomedical, EP Energy, and Avadel Pharmaceuticals Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Aug-09-18 08:00AM  Clearside Biomedical to Participate in 2018 Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-08-18 07:00AM  Clearside Biomedical Announces Second Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire +6.06%
06:30AM  Clearside Biomedical, Inc. to Host Earnings Call ACCESSWIRE
Aug-01-18 08:00AM  Clearside Biomedical to Report Second Quarter 2018 Financial Results on August 8, 2018 Conference Call to Follow GlobeNewswire -7.41%
Jul-16-18 04:30PM  Clearside Biomedical to Present Data from its Pivotal Phase 3 (PEACHTREE) Trial in Macular Edema Associated with Uveitis at the 2018 American Society of Retina Specialists Annual Meeting GlobeNewswire
Jul-11-18 04:30PM  Clearside Biomedical Appoints Carol Hoang as Vice President, Medical Affairs GlobeNewswire
Jul-06-18 07:20AM  Free Technical Research on Clovis Oncology and Three More Biotech Equities ACCESSWIRE
Jun-13-18 04:30PM  Clearside Biomedical Announces Completion of Patient Enrollment in First of Two Phase 3 Clinical Trials of CLS-TA in Retinal Vein Occlusion GlobeNewswire
Jun-11-18 05:00PM  Clearside Biomedical to Participate in 2018 JMP Securities Life Sciences Conference GlobeNewswire
Jun-04-18 07:20AM  Blog Exposure - Clearside Reports Encouraging Data from Phase-2 Trial of CLS-TA Used with Eylea in Patients with Diabetic Macular Edema ACCESSWIRE -5.74%
Jun-01-18 08:55AM  Options Traders Expect Huge Moves in Clearside Biomedical (CLSD) Stock Zacks
08:20AM  Todays Research Reports on Stocks to Watch: Kitov Pharma and Clearside Biomedical ACCESSWIRE
May-31-18 01:30PM  Clearside Biomedical Stock Down 26%: The "Positive" Data That Wasn't Motley Fool -32.19%
07:35AM  Market Trends Toward New Normal in Gaming and Leisure Properties, SMART SAND INC, ARMOUR Residential REIT, Aegon NV, Paratek Pharmaceuticals, and Clearside Biomedical Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
07:30AM  Clearside Biomedical Announces Positive Topline Results from Phase 2 Clinical Trial of CLS-TA Used with Eylea in Patients with Diabetic Macular Edema GlobeNewswire
May-16-18 04:30PM  Clearside Biomedical to Present at the 2018 UBS Global Health Care Conference GlobeNewswire
May-09-18 01:52PM  Markets Make an Art of Unpredictability TheStreet.com +7.83%
07:00AM  Clearside Biomedical Announces First Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
May-02-18 04:30PM  Clearside Biomedical to Report First Quarter 2018 Financial Results on May 9, 2018 Conference Call to Follow GlobeNewswire
Apr-13-18 08:40AM  Why Clearside Biomedical, Inc. Stock Gained 66.1% March Motley Fool
Apr-05-18 08:10AM  Recent Analysis Shows Clearside Biomedical, tronc, Stifel Financial, Woodward, WisdomTree Investments, and Aluminum Corporation of China Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Mar-21-18 08:00AM  Clearside Biomedical to Present at the 17th Annual Needham Healthcare Conference GlobeNewswire
Mar-16-18 10:10AM  3 Hot Junior Biotech Plays Investopedia
Mar-14-18 09:34AM  With A -144.16% Earnings Drop, Did Clearside BioMedical Inc (NASDAQ:CLSD) Really Underperform? Simply Wall St.
07:00AM  Clearside Biomedical Announces Fourth Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire
Mar-08-18 04:45PM  Clearside Biomedical to Report Fourth Quarter and Full Year 2017 Financial Results on March 14, 2018 Conference Call to Follow GlobeNewswire -8.96%
04:15PM  Clearside Biomedical to Present at the Cowen and Company 38th Annual Health Care Conference GlobeNewswire
07:30AM  Report: Developing Opportunities within Owens & Minor, Zosano Pharma, Organovo, Summit Materials, Ralph Lauren, and Clearside Biomedical Future Expectations, Projections Moving into 2018 GlobeNewswire
Mar-07-18 07:37PM  Clearside Announces Pricing of Public Offering of Common Stock GlobeNewswire +10.27%
12:38PM  Why Clearside Biomedical Is Up for a Third Straight Day Motley Fool
07:30AM  Wired News Clearside BioMedical Reported Positive Top-line Results from Phase-3 Trial Assessing CLS-TA in Macular Edema Associated with Non-infectious Uveitis ACCESSWIRE
Mar-06-18 04:01PM  Clearside Announces Proposed Public Offering of Common Stock GlobeNewswire +25.36%
01:40PM  Why Clearside Biomedical Jumped Higher Today Motley Fool
08:20AM  Todays Research Reports on Stocks to Watch: Innovate Biopharmaceuticals and Clearside BioMedical ACCESSWIRE
07:30AM  Clearside Biomedical Provides Update on Two Phase 3 Clinical Trials of CLS-TA in Retinal Vein Occlusion GlobeNewswire
Mar-05-18 03:30PM  Heres Whats Moving Clearside Biomedical, Inc. (NASDAQ:CLSD) Right Now Market Exclusive +32.10%
08:42AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:53AM  Heres Why Clearside Biomedical Inc (CLSD) Shares Soared Today SmarterAnalyst
07:12AM  Clearside Biomedical shares surge 53% premarket on news of positive trial of eye disease treatment MarketWatch
07:00AM  Clearside Biomedical Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial of CLS-TA in Macular Edema Associated with Non-Infectious Uveitis GlobeNewswire
Mar-02-18 04:05PM  Clearside Biomedical Schedules Conference Call to Review Topline Results from Pivotal Phase 3 PEACHTREE Clinical Trial of CLS-TA in Macular Edema Associated with Non-Infectious Uveitis GlobeNewswire +11.24%
Feb-26-18 08:00AM  Clearside Biomedical Announces Organizational Changes Designed to Support Transition to a Commercial-Stage Company GlobeNewswire
Dec-20-17 08:00AM  Clearside Biomedical, Inc. to Present at the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire +5.19%
Dec-14-17 05:05PM  Are Clearside BioMedical Incs (NASDAQ:CLSD) Interest Costs Too High? Simply Wall St. -7.19%
Dec-07-17 01:17PM  ETFs with exposure to Clearside Biomedical, Inc. : December 7, 2017 Capital Cube
Nov-27-17 12:43PM  ETFs with exposure to Clearside Biomedical, Inc. : November 27, 2017 Capital Cube
Nov-21-17 09:13AM  Clearside Biomedical, Inc. :CLSD-US: Earnings Analysis: Q3, 2017 By the Numbers : November 21, 2017 Capital Cube
Nov-13-17 04:30PM  Clearside Biomedical, Inc. to Participate in Stifel 2017 Healthcare Conference GlobeNewswire
07:30AM  Clearside Biomedicals Phase 1/2 Open Label Clinical Trial of CLS-TA With and Without Eylea in Diabetic Macular Edema Presented at the American Academy of Ophthalmology 2017 Annual Meeting GlobeNewswire
Nov-08-17 07:00AM  Clearside Biomedical, Inc. Announces Third Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire
06:50AM  Clearside Biomedical, Inc. to Host Earnings Call ACCESSWIRE
Nov-01-17 08:30AM  Clearside Biomedical, Inc. to Report Third Quarter 2017 Financial Results on November 8, 2017 Conference Call to Follow GlobeNewswire
Oct-24-17 04:30PM  Clearside Biomedical Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CLS-TA Used Together with Eylea in Patients with Diabetic Macular Edema GlobeNewswire
Oct-11-17 11:20AM  ETFs with exposure to Clearside Biomedical, Inc. : October 11, 2017 Capital Cube
Sep-28-17 10:11AM  ETFs with exposure to Clearside Biomedical, Inc. : September 28, 2017 Capital Cube
Aug-31-17 05:45PM  ETFs with exposure to Clearside Biomedical, Inc. : August 31, 2017 Capital Cube
Aug-24-17 10:23AM  Clearside Biomedical, Inc. :CLSD-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 Capital Cube
Aug-09-17 07:00AM  Clearside Biomedical, Inc. Announces Second Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire -10.43%
06:00AM  Investor Network: Clearside Biomedical, Inc. to Host Earnings Call ACCESSWIRE
Aug-08-17 04:05PM  Clearside Biomedical, Inc. Announces Participation in Upcoming Events GlobeNewswire
08:00AM  Clearside Biomedical, Inc. Announces Changes to its Board of Directors GlobeNewswire
Aug-07-17 08:00AM  Clearside Biomedical Announces Completion of Patient Enrollment in Pivotal Phase 3 PEACHTREE Clinical Trial of CLS-TA for Suprachoroidal Administration in Patients with Macular Edema Associated with Non-Infectious Uveitis GlobeNewswire
Aug-02-17 08:00AM  Clearside Biomedical, Inc. to Report Second Quarter 2017 Financial Results on August 9, 2017 Conference Call to Follow GlobeNewswire
Jul-11-17 04:30PM  Clearside Biomedical Announces First Patient Randomized in Phase 2 Clinical Trial of CLS-TA Used Together with Eylea in Patients with Diabetic Macular Edema GlobeNewswire
Jun-13-17 04:30PM  Clearside Biomedical, Inc. to Participate in 2017 JMP Securities Life Sciences Conference GlobeNewswire
Jun-08-17 01:00AM  Clearside Biomedicals TANZANITE Extension Study in Patients with Macular Edema Associated with Retinal Vein Occlusion Presented at the 40th Annual Macula Society Meeting GlobeNewswire +8.72%
May-30-17 12:21PM  ETFs with exposure to Clearside Biomedical, Inc. : May 30, 2017 Capital Cube
May-18-17 08:31AM  Surging Earnings Estimates Signal Good News for Clearside (CLSD) Zacks
May-15-17 03:28PM  ETFs with exposure to Clearside Biomedical, Inc. : May 15, 2017 Capital Cube
May-12-17 10:57AM  Clearside Biomedical, Inc. :CLSD-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017 Capital Cube
May-10-17 07:15AM  Investor Network: Clearside Biomedical, Inc. to Host Earnings Call Accesswire
07:00AM  Clearside Biomedical, Inc. Announces First Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire
May-03-17 07:30AM  Clearside Biomedical, Inc. to Report First Quarter 2017 Financial Results on May 10, 2017 Conference Call to Follow GlobeNewswire
Apr-26-17 04:30PM  Clearside Biomedical, Inc. to Present at the Deutsche Bank 42nd Annual Health Care Conference GlobeNewswire
Apr-20-17 08:00AM  Clearside Biomedical, Inc. Announces Completion of Patient Enrollment in Phase 1/2 Open Label Clinical Trial of CLS-TA in Diabetic Macular Edema GlobeNewswire
Mar-31-17 01:11PM  Edited Transcript of CLSD earnings conference call or presentation 14-Mar-17 12:30pm GMT Thomson Reuters StreetEvents
08:00AM  Clearside Biomedical Enters into Strategic Collaboration with EyeKor to Support Clinical Development Efforts GlobeNewswire
Mar-28-17 08:30AM  Clearside Biomedical, Inc. to Present at the 16th Annual Needham Healthcare Conference GlobeNewswire
Mar-23-17 01:04PM  CLEARSIDE BIOMEDICAL, INC. Financials
Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to treat blinding diseases of the eye. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion; and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase II clinical trial for diabetic macular edema. The company also engages in the development of therapies in various areas, such as gene therapy for inherited retinal disorders, neovascular age-related macular degeneration, and other ocular diseases. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cagle Gerald D.DirectorJun 25Option Exercise8.8811,25099,90280,145Jun 26 06:01 PM
White Daniel H.President and CEOJun 04Buy9.0711,00099,770483,335Jun 04 08:31 PM
Thorp ClayDirectorMay 18Sale13.1661,139804,5893,466,394May 21 04:05 PM
Thorp ClayDirectorMay 17Sale13.03100,0001,303,0003,527,533May 21 04:05 PM
Cagle Gerald D.DirectorMay 11Option Exercise0.4045,45418,18268,895May 15 05:01 PM
Deignan Charles A.Chief Financial OfficerMar 23Buy11.795005,89566,356Mar 26 05:21 PM
Thorp ClayDirectorMar 23Sale12.025,23162,8773,627,533Mar 23 05:51 PM
Cagle Gerald D.DirectorMar 22Buy11.897,50089,17523,441Mar 23 09:17 AM
Thorp ClayDirectorMar 22Sale12.0733,630405,9143,632,764Mar 23 05:51 PM
Thorp ClayDirectorMar 21Sale12.27100,0001,227,0003,666,394Mar 23 05:51 PM
Thorp ClayDirectorDec 07Sale6.135,00030,6503,766,394Dec 07 05:10 PM
Thorp ClayDirectorDec 06Sale6.0915,00091,3503,771,394Dec 07 05:10 PM
Thorp ClayDirectorDec 05Sale6.3715,00095,5503,786,394Dec 07 05:10 PM